INVESTOR ALERT: Federman & Sherwood Investigates Sarepta Therapeutics, Inc.
for Possible Securities Laws Violations
OKLAHOMA CITY -- November 13, 2013
The law firm of Federman & Sherwood has been retained by a shareholder of
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta” or “the Company”) to
investigate Sarepta for possible violations of Sections 10(b) and 20(a) of the
Securities Exchange Act of 1934 and/or breaches of fiduciary duty by the
Company’s officers and directors.
During its Q3 Earnings Conference Call on November 12, 2013, Sarepta announced
that the Food and Drug Administration (“FDA”) had just advised the Company not
to file for accelerated approval of its drug eteplirsen, which is used to
treat Duchenne muscular dystrophy, citing “considerable doubt…on the efficacy
support of eteplirsen.” This delay could push the potential approval of
eteplirsen back by more than 2 years. Once this announcement was made, Sarepta
shares dropped more than 64%, a 52-week low.
Federman & Sherwood is investigating whether Sarepta issued materially false
and/or misleading statements or failed to disclose material facts surrounding
the approval of eteplirsen. If you currently own common stock in Sarepta
Therapeutics, Inc., have any information to assist in our investigation, or
have questions or concerns regarding this notice or your rights or interests
in this matter, please contact William B. Federman at email@example.com.
Federman & Sherwood has extensive nationwide experience in representing
investors in securities, derivative and merger-related shareholder class
actions, and has been appointed as lead counsel in multiple complex cases
across the country.
FEDERMAN & SHERWOOD
William B. Federman, 405-235-1560
Press spacebar to pause and continue. Press esc to stop.